Compare Dyne Therapeutics Inc. Common Stock (DYN) vs iShares MSCI South Korea ETF (EWY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs iShares MSCI South Korea ETF — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while iShares MSCI South Korea ETF trades at $151.19 (market cap $24.38B). The key difference: iShares MSCI South Korea ETF is far larger — about 8.5× Dyne Therapeutics Inc. Common Stock's market cap, and iShares MSCI South Korea ETF is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and iShares MSCI South Korea ETF for 48 Days on average.
| DYN | EWY | |
|---|---|---|
Market Cap | $2.86B | $24.38B |
Volume | 3,341,579 | 22,329,675 |
Sector | Health | Broad Market / Factor |
52-Week High | $26.78 | $219.20 |
52-Week Low | $14.60 | $85.17 |
Typical Hold Time | 0 Days | 48 Days |
Enterprise Value | $2.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
EWY, the iShares MSCI South Korea ETF, is trading at $166.56, down 2.16% amid bearish technical signals. The ETF faces pressure from rising US yields and oil prices impacting South Korean tech stocks, though corporate earnings remain resilient with strong AI memory demand driving performance. Technical indicators show oversold conditions with RSI at 21.77 suggesting potential bounce.
Outlook remains cautious due to concentrated exposure to Samsung and SK hynix, making EWY highly sensitive to semiconductor cycle volatility. While AI infrastructure spending provides growth catalyst, macroeconomic headwinds and profit-taking near 7,000 KOSPI level present near-term risks for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About iShares MSCI South Korea ETF
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →
